Sucrosomial Iron in Patients With Celiac Disease and IDA
Primary Purpose
Celiac Disease, Iron Deficiency Anemia
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
sucrosomial iron
Sulphate iron
Sponsored by
About this trial
This is an interventional treatment trial for Celiac Disease
Eligibility Criteria
Inclusion Criteria:
- proven celiac disease
- iron deficiency anemia
Exclusion Criteria:
- other autoimmne diseases
- pregnancy psychiatric disorders
Sites / Locations
- Fondazione IRCCS Ca' GrandaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
sulphate iron
sucrosomial iron
Arm Description
patients administered with sulphate iron
patients administered with sucrosomial iron
Outcomes
Primary Outcome Measures
Hemoglobin
Secondary Outcome Measures
Full Information
NCT ID
NCT02916654
First Posted
September 21, 2016
Last Updated
March 23, 2017
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
1. Study Identification
Unique Protocol Identification Number
NCT02916654
Brief Title
Sucrosomial Iron in Patients With Celiac Disease and IDA
Official Title
Sucrosomial Iron Supplementation in Anaemic Patients With Celiac Disease Not Tolerating Oral Ferrous Sulfate
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Sucrosomial iron (Sideral® Forte) is a preparation of ferric pyrophosphate conveyed within a phospholipid membrane associated with ascorbic acid, is a new-generation oral iron which shows a high gastrointestinal absorption and high bioavailability with a low incidence of side effects due to lack of any direct contact with intestinal mucosa. In comparison with the other standard oral iron preparations, sucrosomial iron seems to be a promising new strategy of iron replacement in CD patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease, Iron Deficiency Anemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
sulphate iron
Arm Type
Active Comparator
Arm Description
patients administered with sulphate iron
Arm Title
sucrosomial iron
Arm Type
Experimental
Arm Description
patients administered with sucrosomial iron
Intervention Type
Dietary Supplement
Intervention Name(s)
sucrosomial iron
Intervention Description
administration of sucrosomial iron
Intervention Type
Drug
Intervention Name(s)
Sulphate iron
Intervention Description
administration of sulphate iron
Primary Outcome Measure Information:
Title
Hemoglobin
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
proven celiac disease
iron deficiency anemia
Exclusion Criteria:
other autoimmne diseases
pregnancy psychiatric disorders
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luca Elli, MD
Phone
0255033384
Ext
0039
Email
dottorlucaelli@gmail.com
Facility Information:
Facility Name
Fondazione IRCCS Ca' Granda
City
Milano
State/Province
MI
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luca Elli, MD
Phone
0255033384
Ext
0039
Email
dottorlucaelli@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Sucrosomial Iron in Patients With Celiac Disease and IDA
We'll reach out to this number within 24 hrs